Yang, S., Hou, Y., Wang, X., Kang, S., Pan, Z. (2026). Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0353864